Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BIIB vs IOVA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: BIIB 5 – 1 IOVA Matrix Metrics: BIIB 8 – 2 IOVA

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas IOVA carries 70.4/100 (BUY) at $7.63 (N/M Forward P/E, -60.8% operating margin).

  • Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (70.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. -60.8% operating margin) and revenue trajectory (+10.6% vs. +80.1% YoY).
  • Technical & Structure Timing Caution: BIIB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3); meanwhile IOVA is in a Breakdown options structure phase (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BIIB vs IOVA
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03
IOVA NASDAQ
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.63
-1.71% 1D
Market Cap $3.5B
TTM Revenue $379M
Forward P/E N/M
Beta / 30D Vol 1.58β · 144% Vol
Unified Composite Score
70.4 / 100 BUY
Tech 80.0 Fund 70.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 32
RSI-14: 32.5 · SMA20: $10.38 · SMA50: $11.31

6-Pillar Scorecard Institutional Category Breakdown (BIIB 5 – 1 IOVA)

Columns: Metric · BIIB · IOVA
1. Valuation Multiples BIIB
Forward P/E 15.6x N/M
Trailing P/E 109.9x N/M
PEG Ratio 3.45x N/M
EV / Revenue 4.2x 9.3x
2. Growth & Scale IOVA
Revenue Growth (YoY) +10.6% +80.1%
Earnings Growth (YoY) -84.8% +0.0%
TTM Revenue (USD) $10.3B $379M
Market Cap $37.0B $3.5B
3. Profitability & Quality BIIB
Gross Margin 75.8% 53.2%
Operating Margin 23.5% -60.8%
Net Profit Margin 3.4% -58.2%
Return on Equity (ROE) 1.9% -29.1%
4. Balance Sheet & Cash Flow BIIB
Cash Generation (TTM) $1.64B -$216M
Cash Flow Margin 16.0% -57.0%
Net Cash / Leverage $6.50B Net Debt (0.41x D/E) $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 18.4% (6th %ile) 83.9% (25th %ile)
Put/Call OI Skew 0.77x (Call-Skewed) 0.58x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BIIB
OpEx & R&D Intensity 52.3% of Rev ($5.39B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BIIB (8) vs IOVA (2)
Institutional Metric BIIB IOVA Criterion Row Edge
Market Capitalization
Scale
$37.0B $3.5B Larger Scale BIIB
Trailing P/E Ratio
Valuation
109.9x N/M Lower Multiple BIIB
Forward P/E Ratio
Valuation
15.6x N/M Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+10.6% +80.1% Higher Growth IOVA
Operating Margin (TTM)
Profitability
23.5% -60.8% Higher Margin BIIB
Net Profit Margin
Profitability
3.4% -58.2% Higher Margin BIIB
Return on Equity (ROE)
Capital Efficiency
1.9% -29.1% Higher ROE BIIB
52-Week Range Position
Momentum
92% ($160–$261) 42% ($2–$15) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
0.27β · 36% Vol 1.58β · 144% Vol Lower Realized Risk BIIB
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 70.4 / 100 (BUY) Higher Composite IOVA
Trailing 12M Revenue (USD)
Operating Scale
$10.3B $379M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 53.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.45x PEG · 4.2x EV/Rev N/M PEG · 9.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.64B ($6.50B Net Debt (0.41x D/E)) -$216M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +52.63 pp
BIIB: +8.63% · IOVA: -44.0%
3M Horizon BIIB +10.41 pp
BIIB: +18.9% · IOVA: +8.49%
6M Horizon IOVA +93.3 pp
BIIB: +31.69% · IOVA: +124.99%
1Y Horizon IOVA +163.06 pp
BIIB: +53.41% · IOVA: +216.47%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BIIB Revenue IOVA Revenue BIIB Op. Margin IOVA Op. Margin Margin Leader
FY2018 $13.4B N/A 43.8% N/A BIIB
FY2019 $14.4B N/A 49.0% N/A BIIB
FY2020 $13.4B N/A 33.8% N/A BIIB
FY2021 $11.0B N/A 25.9% N/A BIIB
FY2022 $10.2B N/A 29.9% N/A BIIB
FY2023 $9.84B $0M 11.8% -38735.0% BIIB
FY2024 $9.68B $160M 16.9% -240.9% BIIB
FY2025 $9.89B $260M 13.1% -153.1% BIIB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IOVA BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 83.9%
IV Percentile 25th %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IOVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published
IOVA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -60.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BIIB vs IOVA Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas IOVA carries 70.4/100 (BUY) at $7.63 (N/M Forward P/E, -60.8% operating margin). Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (70.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. -60.8% operating margin) and revenue trajectory (+10.6% vs. +80.1% YoY). Technical & Structure Timing Caution: BIIB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3); meanwhile IOVA is in a Breakdown options structure phase (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IOVA leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with IOVA at +80.1% YoY revenue growth and +0.0% YoY earnings growth on $379M TTM revenue (53.2% gross margin, -60.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BIIB cumulative revenue shifted -26.5% while IOVA shifted +62.5%. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IOVA.

BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas IOVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.3x EV/Revenue (-57.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus IOVA (-29.1% ROE) capital efficiency.

In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, IOVA carries 83.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 144% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.